Literature DB >> 22649153

Recognition and handling of discordant negative human epidermal growth factor receptor 2 classification by Oncotype DX in patients with breast cancer.

Matthias Christgen, Nadia Harbeck, Oleg Gluz, Ulrike Nitz, Hans H Kreipe.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22649153     DOI： 10.1200/JCO.2012.42.1990

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  3 in total

Review 1.  [Translational research and diagnostics for breast cancer].

Authors:  H H Kreipe
Journal:  Pathologe       Date:  2012-11       Impact factor: 1.011

2.  The relationship between quantitative human epidermal growth factor receptor 2 gene expression by the 21-gene reverse transcriptase polymerase chain reaction assay and adjuvant trastuzumab benefit in Alliance N9831.

Authors:  Edith A Perez; Frederick L Baehner; Steven M Butler; E Aubrey Thompson; Amylou C Dueck; Farid Jamshidian; Diana Cherbavaz; Carl Yoshizawa; Steven Shak; Peter A Kaufman; Nancy E Davidson; Julie Gralow; Yan W Asmann; Karla V Ballman
Journal:  Breast Cancer Res       Date:  2015-10-01       Impact factor: 6.466

3.  Precise ERBB2 copy number assessment in breast cancer by means of molecular inversion probe array analysis.

Authors:  Matthias Christgen; Jana L van Luttikhuizen; Mieke Raap; Peter Braubach; Lars Schmidt; Danny Jonigk; Friedrich Feuerhake; Ulrich Lehmann; Brigitte Schlegelberger; Hans H Kreipe; Doris Steinemann
Journal:  Oncotarget       Date:  2016-12-13
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.